免疫监视
乳腺癌
谷氨酰胺
癌症
脑转移
生物
癌症研究
医学
转移
内科学
癌细胞
转移性乳腺癌
氨基酸
生物化学
作者
Pravat Kumar Parida,Mauricio Marquez-Palencia,Vidhya R. Nair,Akash K. Kaushik,Kangsan Kim,Jessica Sudderth,Eduardo Quesada-Diaz,Ámbar Cajigas,Vamsidhara Vemireddy,Paula I. González-Ericsson,Melinda E. Sanders,Bret C. Mobley,Kenneth E. Huffman,Sunati Sahoo,Prasanna Alluri,Cheryl Lewis,Yan Peng,Robert Bachoo,Carlos L. Arteaga,Ariella B. Hanker
出处
期刊:Cell Metabolism
[Cell Press]
日期:2022-01-01
卷期号:34 (1): 90-105.e7
被引量:62
标识
DOI:10.1016/j.cmet.2021.12.001
摘要
HER2+ breast cancer patients are presented with either synchronous (S-BM), latent (Lat), or metachronous (M-BM) brain metastases. However, the basis for disparate metastatic fitness among disseminated tumor cells of similar oncotype within a distal organ remains unknown. Here, employing brain metastatic models, we show that metabolic diversity and plasticity within brain-tropic cells determine metastatic fitness. Lactate secreted by aggressive metastatic cells or lactate supplementation to mice bearing Lat cells limits innate immunosurveillance and triggers overt metastasis. Attenuating lactate metabolism in S-BM impedes metastasis, while M-BM adapt and survive as residual disease. In contrast to S-BM, Lat and M-BM survive in equilibrium with innate immunosurveillance, oxidize glutamine, and maintain cellular redox homeostasis through the anionic amino acid transporter xCT. Moreover, xCT expression is significantly higher in matched M-BM brain metastatic samples compared to primary tumors from HER2+ breast cancer patients. Inhibiting xCT function attenuates residual disease and recurrence in these preclinical models.
科研通智能强力驱动
Strongly Powered by AbleSci AI